MedPath

Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke

Phase 4
Completed
Conditions
Stroke
Interventions
Registration Number
NCT00153946
Lead Sponsor
Combination Therapy for Acute Ischemic Stroke Study Group
Brief Summary

Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
814
Inclusion Criteria
  • Acute ischemic stroke < 24 hours of onset
  • Measurable neurological deficits caused by the present attack, ranging from 1 to 22 of NIHSS score on admission
Read More
Exclusion Criteria
  • Definite or possible cardiogenic brain infarction
  • Definite lacunar infarction
  • Prior ischemic stroke within 6 months
  • Evidence of hemorrhagic brain infarction, epidural hematoma, intracerebral hematoma, or intraventricular hemorrhage
  • Severe consciousness disturbances (semicoma to deep coma)
  • Neurological signs clearing spontaneously
  • Disability of 2 or more on mRS score before the index stroke aPTT being out of the normal range or 1.5 times longer than the pretreatment value
  • If taking an oral anticoagulant, INR being 1.6 or more, or no INR data
  • Treatment with urokinase, t-PA, heparin, ozagrel sodium, warfarin, or antiplatelet except for aspirin before enrollment
  • Intravascular surgery, surgical operation, hyperbaric oxygen therapy, or hypothermia therapy before enrollment
  • Serum creatinine >1.5 mg/dL
  • Severe hepatic or cardiac disorders, infectious disorders, dehydration, etc.
  • Neoplasm
  • Pregnancy
  • Hypersensitivity to test drugs
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BEdaravoneThe patients who are allocated to Edaravone-Argatroban combination therapy
AEdaravoneThe patients who are allocated to Argatroban monotherapy
Primary Outcome Measures
NameTimeMethod
Modified Rankin Scale (MRS) scoreat 3 months
Symptomatic intracranial hemorrhagefor the initial 3 weeks
Secondary Outcome Measures
NameTimeMethod
NIHSS score, JSS score, Barthel Index, modified Rankin Scale scoreat various time-points
Various adverse effectsfor the 3 months

Trial Locations

Locations (1)

EAST Study Office c/o National Cardiovascular Center

🇯🇵

Suita, Osaka, Japan

© Copyright 2025. All Rights Reserved by MedPath